Le Lézard
Classified in: Health, Science and technology, Business
Subjects: TNM, ACC

Dutch State Announces the Sale of Intravacc B.V. (The Netherlands)


DEN HAGUE, Netherlands, May 3, 2023 /PRNewswire/ -- The State of the Netherlands, the Dutch Ministry of Health, Welfare and Sport today announces its intentions to sell 100% of the issued and outstanding shares in the capital of Intravacc B.V. through a controlled auction process.

Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is an established independent contract development and manufacturing organization for infectious diseases and therapeutic vaccines. As an CDMO with many years of experience in the development and optimization of vaccines and vaccine technologies, Intravacc has transferred its technology world-wide for many vaccines, including polio, measles, DTP, Hib and influenza. Intravacc offers a wide range of expertise for independent vaccine development, from proof-of-concept to Phase I/II clinical studies for partners around the world, including universities, public health organizations, biotech and pharmaceutical companies.

See as appendix the advertisement.

Contact info

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 538 16 427
E: [email protected]

Ernst & Young (EY) Strategy and Transactions, financial adviser to the Dutch State, at [email protected].

PDF: https://mma.prnewswire.com/media/2068627/Intravacc_Advertisement_FT.pdf
Logo: https://mma.prnewswire.com/media/1334670/Intravacc_Logo.jpg

 

SOURCE Intravacc


These press releases may also interest you

at 07:00
New Campaign from The Trial for #ClinicalEquality ? "Worth Less" ?Spotlights the Cost of Clinical Inequality
In recognition of Clinical Trials Day, The Trial for #ClinicalEquality ?a longstanding and widely celebrated initiative from FCB Health New York, an IPG Health company ? continues the fight to increase equity in clinical trials with the next phase of...

at 06:52
Global Prenatal Testing Market Projected to Reach $19.8 Billion by 2028
According to the latest BCC Research study, the demand for the Global Prenatal Testing Market is expected to grow from $10.9 billion in 2023 and is projected to reach $19.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 12.6%...

at 06:32
Enhancing Healthcare: A Global Market Study of Medical Robotics and Computer-Assisted Surgery
"According to the latest BCC Research study, the demand for Medical Robotics and Computer-assisted Surgery: The Global Market is expected to grow from $11.5 billion in 2023 and is projected to reach $19.5 billion by the end of 2028, at a compound...

at 06:15
Karmanos Welcomes Wasif Saif, M.D., to Lead Phase 1 Clinical Trials
The Barbara Ann Karmanos Cancer Institute welcomes Wasif Saif, M.D., MBBS, as the new leader of the Phase 1 Clinical Trials Multidisciplinary Team and co-leader of the Gastrointestinal (GI) and Neuroendocrine Oncology Multidisciplinary Team...

at 06:07
Seed Health to Present New Clinical Data on 'DS-01® Daily Synbiotic' for Both Antibiotic Recovery and IBS at Digestive Disease Week 2024
Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two...

at 06:05
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
Arrowhead Pharmaceuticals, Inc. today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS)...

More news about Health...


News published on and distributed by: